1. Home
  2. TTGT vs AUTL Comparison

TTGT vs AUTL Comparison

Compare TTGT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TechTarget Inc.

TTGT

TechTarget Inc.

HOLD

Current Price

$4.20

Market Cap

416.4M

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$1.60

Market Cap

407.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTGT
AUTL
Founded
1999
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
416.4M
407.2M
IPO Year
2024
2025

Fundamental Metrics

Financial Performance
Metric
TTGT
AUTL
Price
$4.20
$1.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$10.75
$8.50
AVG Volume (30 Days)
583.2K
1.6M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,120,000.00
Revenue This Year
$4.45
$80.32
Revenue Next Year
$2.75
$53.96
P/E Ratio
N/A
N/A
Revenue Growth
N/A
496.00
52 Week Low
$3.41
$1.18
52 Week High
$9.00
$2.70

Technical Indicators

Market Signals
Indicator
TTGT
AUTL
Relative Strength Index (RSI) 38.91 47.18
Support Level $3.52 $1.27
Resistance Level $4.75 $1.73
Average True Range (ATR) 0.39 0.14
MACD -0.09 -0.00
Stochastic Oscillator 0.38 32.68

Price Performance

Historical Comparison
TTGT
AUTL

About TTGT TechTarget Inc.

TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. The company provides marketing and sales services that deliver business impact for enterprise technology companies. It develops editorial content across multiple technology-focused websites and channels to engage audiences researching information technology solutions. The company generates revenue by providing market insight and market access to the technology market, including enterprise technology, artificial intelligence, channel, cybersecurity, media & entertainment, and service providers. Geographically, it derives the majority of revenue from North America.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: